Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

ClinicalTrials.gov ID: NCT02802345

Public ClinicalTrials.gov record NCT02802345. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment

Study identification

NCT ID: NCT02802345
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Boehringer Ingelheim; Industry
Enrollment: 274 participants

Conditions and interventions

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

Nintedanib Drug
Placebo Drug
Sildenafil Drug

Drug

Eligibility (public fields only)

Age range: 40 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 29, 2016
Primary completion: Dec 18, 2017
Completion: Apr 12, 2018
Last update posted: Jan 10, 2019

2016 – 2018

United States locations

U.S. sites: 17
U.S. states: 15
U.S. cities: 16

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294	—
Pulmonary Assoc of Stamford	Stamford	Connecticut	06902-3633	—
University of Florida College of Medicine	Jacksonville	Florida	32209	—
University of Chicago	Chicago	Illinois	60637	—
University of Kansas Medical Center	Kansas City	Kansas	66160	—
Michigan Clinical Research Unit	Ann Arbor	Michigan	48109	—
Minnesota Lung Center	Minneapolis	Minnesota	55407	—
The Lung Research Center, LLC	Chesterfield	Missouri	63017	—
NewYork-Presbyterian/Weill Cornell Medical Center	New York	New York	10065	—
Duke University Medical Center	Durham	North Carolina	27710	—
Clinical Research Solutions	Dayton	Ohio	45409	—
Mercy Respiratory Specialist	Toledo	Ohio	43608	—
The Oregon Clinic	Portland	Oregon	97220	—
Lowcountry Lung and Crit Care	Charleston	South Carolina	29406	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
University of Texas Southwestern Medical Center	Dallas	Texas	75235	—
Pulmonary Associates of Richmond, Inc.	Richmond	Virginia	23225	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 68 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02802345, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 10, 2019 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02802345 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →